Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
Identifieur interne : 001A57 ( PubMed/Curation ); précédent : 001A56; suivant : 001A58Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
Auteurs : Qingang Yang [République populaire de Chine] ; Lili Chen ; Xuchang He ; Zhenting Gao ; Xu Shen ; Donglu BaiSource :
- Chemical & pharmaceutical bulletin [ 0009-2363 ] ; 2008.
Descripteurs français
- KwdFr :
- Antisérotonines (pharmacologie), Antisérotonines (synthèse chimique), Antiviraux (pharmacologie), Antiviraux (synthèse chimique), Cinansérine (analogues et dérivés), Cinansérine (pharmacologie), Cinansérine (synthèse chimique), Conception de médicament, Cysteine endopeptidases, Indicateurs et réactifs, Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (synthèse chimique), Modèles moléculaires, Protéines virales (antagonistes et inhibiteurs), Relation structure-activité, Spectrophotométrie IR, Spectroscopie par résonance magnétique, Transfert d'énergie par résonance de fluorescence, Virus du SRAS (enzymologie).
- MESH :
- analogues et dérivés : Cinansérine.
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Virus du SRAS.
- pharmacologie : Antisérotonines, Antiviraux, Cinansérine, Inhibiteurs de protéases.
- synthèse chimique : Antisérotonines, Antiviraux, Cinansérine, Inhibiteurs de protéases.
- Conception de médicament, Cysteine endopeptidases, Indicateurs et réactifs, Modèles moléculaires, Relation structure-activité, Spectrophotométrie IR, Spectroscopie par résonance magnétique, Transfert d'énergie par résonance de fluorescence.
English descriptors
- KwdEn :
- Antiviral Agents (chemical synthesis), Antiviral Agents (pharmacology), Cinanserin (analogs & derivatives), Cinanserin (chemical synthesis), Cinanserin (pharmacology), Cysteine Endopeptidases, Drug Design, Fluorescence Resonance Energy Transfer, Indicators and Reagents, Magnetic Resonance Spectroscopy, Models, Molecular, Protease Inhibitors (chemical synthesis), Protease Inhibitors (pharmacology), SARS Virus (enzymology), Serotonin Antagonists (chemical synthesis), Serotonin Antagonists (pharmacology), Spectrophotometry, Infrared, Structure-Activity Relationship, Viral Proteins (antagonists & inhibitors).
- MESH :
- chemical , analogs & derivatives : Cinanserin.
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemical synthesis : Antiviral Agents, Cinanserin, Protease Inhibitors, Serotonin Antagonists.
- chemical , pharmacology : Antiviral Agents, Cinanserin, Protease Inhibitors, Serotonin Antagonists.
- chemical : Cysteine Endopeptidases, Indicators and Reagents.
- enzymology : SARS Virus.
- Drug Design, Fluorescence Resonance Energy Transfer, Magnetic Resonance Spectroscopy, Models, Molecular, Spectrophotometry, Infrared, Structure-Activity Relationship.
Abstract
The severe acute respiratory syndrome (SARS) coronavirus 3CL protease is an attractive target for the development of anti-SARS drugs. In this paper, cinanserin (1) analogs were synthesized and tested for the inhibitory activities against SARS-coronavirus (CoV) 3CL protease by fluorescence resonance energy transfer (FRET) assay. Four analogs show significant activities, especially compound 26 with an IC(50) of 1.06 microM.
DOI: 10.1248/cpb.56.1400
PubMed: 18827378
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A57
Links to Exploration step
pubmed:18827378Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.</title>
<author><name sortKey="Yang, Qingang" sort="Yang, Qingang" uniqKey="Yang Q" first="Qingang" last="Yang">Qingang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Lili" sort="Chen, Lili" uniqKey="Chen L" first="Lili" last="Chen">Lili Chen</name>
</author>
<author><name sortKey="He, Xuchang" sort="He, Xuchang" uniqKey="He X" first="Xuchang" last="He">Xuchang He</name>
</author>
<author><name sortKey="Gao, Zhenting" sort="Gao, Zhenting" uniqKey="Gao Z" first="Zhenting" last="Gao">Zhenting Gao</name>
</author>
<author><name sortKey="Shen, Xu" sort="Shen, Xu" uniqKey="Shen X" first="Xu" last="Shen">Xu Shen</name>
</author>
<author><name sortKey="Bai, Donglu" sort="Bai, Donglu" uniqKey="Bai D" first="Donglu" last="Bai">Donglu Bai</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18827378</idno>
<idno type="pmid">18827378</idno>
<idno type="doi">10.1248/cpb.56.1400</idno>
<idno type="wicri:Area/PubMed/Corpus">001A57</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A57</idno>
<idno type="wicri:Area/PubMed/Curation">001A57</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.</title>
<author><name sortKey="Yang, Qingang" sort="Yang, Qingang" uniqKey="Yang Q" first="Qingang" last="Yang">Qingang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Lili" sort="Chen, Lili" uniqKey="Chen L" first="Lili" last="Chen">Lili Chen</name>
</author>
<author><name sortKey="He, Xuchang" sort="He, Xuchang" uniqKey="He X" first="Xuchang" last="He">Xuchang He</name>
</author>
<author><name sortKey="Gao, Zhenting" sort="Gao, Zhenting" uniqKey="Gao Z" first="Zhenting" last="Gao">Zhenting Gao</name>
</author>
<author><name sortKey="Shen, Xu" sort="Shen, Xu" uniqKey="Shen X" first="Xu" last="Shen">Xu Shen</name>
</author>
<author><name sortKey="Bai, Donglu" sort="Bai, Donglu" uniqKey="Bai D" first="Donglu" last="Bai">Donglu Bai</name>
</author>
</analytic>
<series><title level="j">Chemical & pharmaceutical bulletin</title>
<idno type="ISSN">0009-2363</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemical synthesis)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cinanserin (analogs & derivatives)</term>
<term>Cinanserin (chemical synthesis)</term>
<term>Cinanserin (pharmacology)</term>
<term>Cysteine Endopeptidases</term>
<term>Drug Design</term>
<term>Fluorescence Resonance Energy Transfer</term>
<term>Indicators and Reagents</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Models, Molecular</term>
<term>Protease Inhibitors (chemical synthesis)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>SARS Virus (enzymology)</term>
<term>Serotonin Antagonists (chemical synthesis)</term>
<term>Serotonin Antagonists (pharmacology)</term>
<term>Spectrophotometry, Infrared</term>
<term>Structure-Activity Relationship</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antisérotonines (pharmacologie)</term>
<term>Antisérotonines (synthèse chimique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (synthèse chimique)</term>
<term>Cinansérine (analogues et dérivés)</term>
<term>Cinansérine (pharmacologie)</term>
<term>Cinansérine (synthèse chimique)</term>
<term>Conception de médicament</term>
<term>Cysteine endopeptidases</term>
<term>Indicateurs et réactifs</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Inhibiteurs de protéases (synthèse chimique)</term>
<term>Modèles moléculaires</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Relation structure-activité</term>
<term>Spectrophotométrie IR</term>
<term>Spectroscopie par résonance magnétique</term>
<term>Transfert d'énergie par résonance de fluorescence</term>
<term>Virus du SRAS (enzymologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cinanserin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term>
<term>Cinanserin</term>
<term>Protease Inhibitors</term>
<term>Serotonin Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Cinanserin</term>
<term>Protease Inhibitors</term>
<term>Serotonin Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Cysteine Endopeptidases</term>
<term>Indicators and Reagents</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Cinansérine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antisérotonines</term>
<term>Antiviraux</term>
<term>Cinansérine</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antisérotonines</term>
<term>Antiviraux</term>
<term>Cinansérine</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Design</term>
<term>Fluorescence Resonance Energy Transfer</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Models, Molecular</term>
<term>Spectrophotometry, Infrared</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term>
<term>Cysteine endopeptidases</term>
<term>Indicateurs et réactifs</term>
<term>Modèles moléculaires</term>
<term>Relation structure-activité</term>
<term>Spectrophotométrie IR</term>
<term>Spectroscopie par résonance magnétique</term>
<term>Transfert d'énergie par résonance de fluorescence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome (SARS) coronavirus 3CL protease is an attractive target for the development of anti-SARS drugs. In this paper, cinanserin (1) analogs were synthesized and tested for the inhibitory activities against SARS-coronavirus (CoV) 3CL protease by fluorescence resonance energy transfer (FRET) assay. Four analogs show significant activities, especially compound 26 with an IC(50) of 1.06 microM.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18827378</PMID>
<DateCompleted><Year>2008</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0009-2363</ISSN>
<JournalIssue CitedMedium="Print"><Volume>56</Volume>
<Issue>10</Issue>
<PubDate><Year>2008</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Chemical & pharmaceutical bulletin</Title>
<ISOAbbreviation>Chem. Pharm. Bull.</ISOAbbreviation>
</Journal>
<ArticleTitle>Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.</ArticleTitle>
<Pagination><MedlinePgn>1400-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The severe acute respiratory syndrome (SARS) coronavirus 3CL protease is an attractive target for the development of anti-SARS drugs. In this paper, cinanserin (1) analogs were synthesized and tested for the inhibitory activities against SARS-coronavirus (CoV) 3CL protease by fluorescence resonance energy transfer (FRET) assay. Four analogs show significant activities, especially compound 26 with an IC(50) of 1.06 microM.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Qingang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo><Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Xuchang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Zhenting</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Xu</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bai</LastName>
<ForeName>Donglu</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Japan</Country>
<MedlineTA>Chem Pharm Bull (Tokyo)</MedlineTA>
<NlmUniqueID>0377775</NlmUniqueID>
<ISSNLinking>0009-2363</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007202">Indicators and Reagents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>KI6J9OY7A3</RegistryNumber>
<NameOfSubstance UI="D002928">Cinanserin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002928" MajorTopicYN="N">Cinanserin</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007202" MajorTopicYN="N">Indicators and Reagents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013055" MajorTopicYN="N">Spectrophotometry, Infrared</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18827378</ArticleId>
<ArticleId IdType="pii">JST.JSTAGE/cpb/56.1400</ArticleId>
<ArticleId IdType="doi">10.1248/cpb.56.1400</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:18827378 |texte= Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18827378" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |